FOSUN INTL (00656): Total revenue for the first half of 2026 reached 86.96 billion yuan, with net profit attributable to the parent company increasing by 160.3% year-on-year.

On August 27, 2026, FOSUN INTL (00656) and its subsidiaries (collectively referred to as "Fosun" or "the Group") announced their interim performance for the six months ending June 30, 2026 (hereinafter referred to as "the Reporting Period"). In the first half of 2026, Fosun continued to advance its strategy of "streamlining and focusing on core businesses." Driven by a "dual engine" of innovation and globalization, the operational quality of its core industries, including pharmaceuticals, health, insurance, finance, and cultural tourism, steadily improved, resonating upwards and enhancing profit quality. During the Reporting Period, the Group's total revenue reached RMB 86.96 billion, maintaining stability while continuously exiting non-strategic and non-core assets; operational profit from industries reached RMB 3.69 billion, a year-on-year increase of 17%; the profit attributable to shareholders of the parent company amounted to RMB 1.72 billion, with a substantial year-on-year growth of 160.3%. During the Reporting Period, Fosun's asset base remained robust. The revenues of its subsidiaries, including Shanghai Fosun Pharmaceutical, Shanghai Yuyuan Tourist Mart, Fosun Portugal Insurance, and the Fosun Tourism segment, totaled RMB 63.88 billion, accounting for 73.5% of the Group's total revenue. Overseas revenue reached RMB 49.16 billion, an increase of 5.3% year-on-year, with its share of total revenue rising by 3 percentage points compared to the same period in 2025 to 56.5%, fully validating the effectiveness of globalization. Meanwhile, Fosun adhered to proactive and prudent liquidity and debt management, maintaining a sufficient liquidity buffer. During the Reporting Period, the Group completed the exit of non-strategic and non-core assets, returning over RMB 12 billion in value. As of June 30, 2026, cash and bank balances along with time deposits were RMB 61.214 billion, an increase from the end of 2025; the total debt-to-capital ratio was 55.7%, further declining from the end of 2025. A healthy debt ratio and ample cash reserves not only enhanced the Group's ability to withstand risks but also increased its capacity to seize investment opportunities. FOSUN INTL Chairman Guo Guangchang stated: "In recent years, Fosun has resolutely advanced the strategy of 'streamlining and focusing on core businesses' and completed systemic adjustments while the sun shines. The performance recovery in the first half of this year fully validates that our strategic choices and continuous focus are correct. Fosun is now back on the growth track, and we will develop even faster along this path in the future." Adhering to innovation-driven strategies, the approval of innovative drugs has accelerated, realizing value. In the first half of 2026, Fosun maintained an innovation-driven approach, fully embracing AI applications to accelerate the realization of scientific and technological achievements and continuously improve operational efficiency. During the Reporting Period, Fosun's investment in scientific innovation reached RMB 4.2 billion, an increase of 16.7% year-on-year. The "self-research + investment incubation + ecological cooperation" three-pronged global innovation system continued to gain momentum, yielding a range of globally competitive innovative results. Focusing on unmet clinical needs, the health sector's scientific innovations shone brightly. During the Reporting Period, innovative drugs entered a dense approval phase, with Shanghai Fosun Pharmaceutical's seven innovative drugs collectively approved for 20 indications both domestically and overseas. Among these, Revcovi (Luvotremir) was approved for the treatment of recurrent or refractory Langerhans cell histiocytosis in children and adolescents, continuing to tackle the treatment void for rare diseases. In the field of neurodegenerative diseases, Shanghai Fosun Pharmaceutical continued to advance its innovative layout: based on its previously obtained development, registration, production, and exclusive commercialization rights in mainland China, Hong Kong, Macau, and a designated ten Southeast Asian countries, it further gained global exclusive options for AR1001, allowing it to exercise its option to expand the licensed area into key markets worldwide including the U.S., Europe, and Japan and to act as the marketing authorization holder in these regions; confirmatory clinical trials for sodium mannitol capsules are steadily progressing after their launch in mainland China, with over 1,000 cases enrolled as of July 31, 2026; the oral brain-penetrating NLRP3 inhibitor HT001, introduced by the incubated enterprise Hengtai Biotechnology, has initiated Phase I clinical trials in Australia. As a core subsidiary of the health sector, Shanghai Fosun Pharmaceutical achieved operating revenue of RMB 20.377 billion in the first half of the year, with innovative drug revenue growing by 13.84% year-on-year, increasing its contribution to 33.35% of pharmaceutical business revenue, becoming a core engine of growth. In the field of biopharmaceutical innovation, Fosun made constant breakthroughs in the first half of the year. The HENLIUS-developed drug for perioperative gastric cancer was approved by the China National Medical Products Administration, becoming the world's first and only anti-PD-1 monoclonal antibody approved for this indication, pioneering the new paradigm of "postoperative de-chemotherapy." The core asset of the innovative pipeline, HLX43, as a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, has shown preliminary clinical efficacy in multiple solid tumors, such as non-small cell lung cancer, demonstrating "high efficiency and low toxicity." Currently, more than ten single-agent or combination clinical trials have been conducted, enrolling over 1,500 patients globally, continually validating its broad therapeutic potential in various solid tumors. During the Reporting Period, HENLIUS demonstrated strong endogenous growth momentum and high-quality hematopoietic capability, achieving revenue of RMB 3.5882 billion, a year-on-year increase of 27.3%; net profit was RMB 430.4 million, a year-on-year increase of 10.3%. In the face of the AI wave, Fosun is delving into AI applications around core businesses and global industrial ecology, focusing on "pragmatic productivity" to create genuine industrial value. Shanghai Fosun Pharmaceutical completed the upgrade of its PharmAID Medical Intelligence System V2.0, forming four major segments and leading product pipelines through AI empowerment across the full lifecycle from early R&D to clinical confirmation and post-marketing. As of the end of the Reporting Period, Shanghai Fosun Pharmaceutical had over 25 high-value AI projects in operation and more than 50 scenarios progressing in parallel, covering assessment of pharmaceutical projects, target predictions, molecular optimizations, and all business lines. Two AI-assisted generated and structured new molecules have entered the preclinical candidate phase. In March 2026, HENLIUS's self-developed new generation rHuPH20 excipient injection was approved for clinical use in China, with the enzyme molecular design cycle shortened from the original 18 months to just 5 months through its "AI for Science" platform. Beyond pharmaceuticals, AI has been deeply integrated across Fosun's cultural tourism, insurance, and smart manufacturing businesses. The Fosun Tourism segment accelerated the implementation of AI G.O, collaborating with leading tech enterprises to deeply cooperate on empowering guest experiences, transforming cloud and AI-native platforms, and global growth across three major directions. Hainan Mining quickly positioned itself in upstream core resources such as fluorite mines, driven by the resource demands brought by AI technology. With globalization deeply operating to enhance quality and efficiency, the overall performance of domestic and overseas insurance companies has improved. Leveraging its industrial layout and deep operations across over 40 countries and regions, Fosun is fully advancing its strategy of "linking Chinese capabilities to global resources," integrating China's manufacturing capacity, service capabilities, and innovation dividends into global markets. During the Reporting Period, the Group's overseas revenue reached RMB 49.16 billion, accounting for 56.5% of total revenue. In the first half of 2026, the globalization capabilities of Fosun's enterprises continued to enhance, achieving significant breakthroughs in its "going global" business. In the field of pharmaceuticals, Shanghai Fosun Pharmaceutical's overseas business revenue grew by 16.45% year-on-year, raising its proportion of total revenue to 31.30%, a year-on-year increase of 3.11 percentage points, with revenue structure continuing to optimize. HENLIUS's drugs were approved for three new indications in the European Union, and HLX11 (Pertuzumab Injection) was also approved in the EU, while HLX14 (Dexamethasone Injection) was approved and successfully commercialized in Canada. To date, HENLIUS has had 10 products approved globally in over 60 countries and regions, covering Asia, Europe, Latin America, North America, and Oceania, benefiting over 1.1 million patients. Fosun Health continues to push forward its internationalization process, actively expanding into markets in Indonesia, Bangladesh, Mongolia, and the Hong Kong-Macau region to establish an open, stable, and professional international medical cooperation network. Additionally, the brand-new International Medical Center building of Fosun Zancheng Hospital in Foshan has been put into use, completing a full-process international medical service closed loop. In the consumer and cultural tourism sectors, in the first half of 2026, Shanghai Yuyuan Tourist Mart's revenue in the China Hong Kong and Macau region reached RMB 532 million, a year-on-year increase of 285.83%; revenue from the Japanese market reached RMB 306 million, an increase of 6.09%. The jewelry segments overseas expansion achievements were remarkable, with Lao Miao opening five new stores in Hong Kong, Macau, and overseas duty-free locations, currently reaching a total of 15 in those channels. Club Med has continued to advance its global destination layout, with the Club Med Mediterranean White Ark Resort in Hangzhou Longwu officially opening in April 2026, and the Club Med Southern Africa Beach and Safari Resort starting trial operations in July 2026. In the smart manufacturing sector, Hainan Mining's integrated industrial chain for Marlboro Lithium Mine + Hainan Star Sea Lithium Salt Processing is operating steadily, becoming the core engine for the company's performance growth. In the first half of the year, three batches totaling 70,000 tons of lithium concentrate were shipped from Mali, Africa to Yangpu Port, Hainan, China. The phosphate ester flame retardant project located in Thailand by Zhejiang Wansheng was successfully put into production, filling a gap in overseas manufacturing and injecting new resilience into the global supply chain. With the in-depth promotion of the globalization strategy, the performance of Fosun's domestic and overseas insurance companies showed broad improvement in the first half of 2026. As of the end of the Reporting Period, Fosun Portugal Insurance's overall share reached 30.1% in the Portuguese market, with international business accounting for 26.7% of total consolidated business volume, and total gross premiums in overseas markets reached 1.035 billion. During the Reporting Period, despite losses from multiple storms in Portugal, Fosun Portugal Insurance still achieved a net profit attributable to its parent of 165 million, a year-on-year increase of 23.8%. Dingrui Reinsurance maintained steady performance due to its high-quality customer base, rigorous underwriting discipline, and global business layout. In the Reporting Period, reinsurance revenue and gross premiums increased by 25.0% and 11.8% year-on-year, respectively, with a net profit after tax of USD 89.7 million. With robust financial strength and a continuously improving market position, Moody's upgraded Dingrui Reinsurances rating from Baa1 to A3 in April 2026, with a stable rating outlook. Domestically, Fosun Baode Insurance's scale premiums reached RMB 8.38 billion in the first half of 2026, a year-on-year growth of 52.2%; net profit reached RMB 780 million, a year-on-year increase of 270%, with the net profit exceeding the total for the entire year of 2025. Fosun Union Health Insurance achieved a revenue increase of 36.2% year-on-year, with a net profit of RMB 572 million. Adhering to commercial goodness, MSCI ESG rating upgraded to the highest level of AAA. During the Reporting Period, Fosun continued to receive international recognition in the field of environmental, social, and governance (ESG). The MSCI ESG rating was upgraded to the highest level of AAA, and Fosun was successfully selected again for the S&P Global "Sustainable Development Yearbook 2026," ranking within the top 1% in the "Sustainable Development Yearbook (China Edition) 2026." Moreover, FTSE ESG ratings continued to lead the average level of global industries and Chinese enterprises, and for five consecutive years, Fosun has been included in the FTSE Russell Social Responsibility Index (FTSE4Good Index Series). Fosun continues to contribute Chinese solutions to anti-malaria efforts in Africa. By the end of the Reporting Period, Shanghai Fosun Pharmaceutical had supplied over 460 million doses of artesunate for injection globally, saving over 92 million severe malaria patients. The "seasonal malaria drug prevention project," centered around SPAQ-CO series products, has benefited over 330 million African children. The Fosun Foundation's "Village Doctor Program" continues to cover 78 project counties across 16 provinces, cities, and autonomous regions, safeguarding 25,000 village doctors and benefiting 3 million rural families and 16.34 million rural residents. In the first half of 2026, over 12,590 group accident and critical illness insurance policies were purchased for village doctors in project counties, and smart upgrades were implemented in 59 health clinics, assisting 263 village doctors in obtaining qualifications as rural general practitioners. The AI Village Doctor Assistant 2.0 launched in May has a success rate of 100%, with user satisfaction among village doctors reaching 92%. Looking ahead, Guo Guangchang stated: "The recovery of our performance in the first half of the year is not accidental but an inevitable result of Fosun's adherence to long-termism and persistent focus on core businesses. Moving forward, we will continue to advance innovation-driven and global development centered around our advantageous industries. Along this certain trajectory, we are confident in progressively restoring profits to the scale of tens of billions of RMB."